These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 16382258

  • 21. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
    Mega JL, Hochman JS, Scirica BM, Murphy SA, Sloan S, McCabe CH, Merlini P, Morrow DA.
    Circulation; 2010 Apr 27; 121(16):1809-17. PubMed ID: 20385930
    [Abstract] [Full Text] [Related]

  • 22. Metabolic modulation: a new therapeutic target in treatment of heart failure.
    Palaniswamy C, Mellana WM, Selvaraj DR, Mohan D.
    Am J Ther; 2011 Nov 27; 18(6):e197-201. PubMed ID: 20393344
    [Abstract] [Full Text] [Related]

  • 23. Metabolic management of ischemic heart disease: clinical data with trimetazidine.
    Desideri A, Celegon L.
    Am J Cardiol; 1998 Sep 03; 82(5A):50K-53K. PubMed ID: 9737486
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E, Buros JL, Chaitman BR, Morrow DA.
    J Am Coll Cardiol; 2009 Apr 28; 53(17):1510-6. PubMed ID: 19389561
    [Abstract] [Full Text] [Related]

  • 25. Metabolic agents in the management of diabetic coronary patients: a new era.
    Marazzi G, Volterrani M, Rosano GM.
    Int J Cardiol; 2008 Jun 23; 127(1):124-5. PubMed ID: 18199501
    [Abstract] [Full Text] [Related]

  • 26. Modulation of myocardial metabolism: an emerging therapeutic principle.
    Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL.
    Curr Opin Cardiol; 2010 Jul 23; 25(4):329-34. PubMed ID: 20535068
    [Abstract] [Full Text] [Related]

  • 27. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.
    Rehberger-Likozar A, Šebeštjen M.
    Coron Artery Dis; 2015 Dec 23; 26(8):651-6. PubMed ID: 26049922
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
    Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E, MERLIN-TIMI 36 Investigators.
    Am Heart J; 2006 Jun 23; 151(6):1186.e1-9. PubMed ID: 16781216
    [Abstract] [Full Text] [Related]

  • 29. Mechanism of action of the new anti-ischemia drug ranolazine.
    Hasenfuss G, Maier LS.
    Clin Res Cardiol; 2008 Apr 23; 97(4):222-6. PubMed ID: 18046526
    [Abstract] [Full Text] [Related]

  • 30. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
    Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC.
    J Pharmacol Exp Ther; 2007 Apr 23; 321(1):213-20. PubMed ID: 17202401
    [Abstract] [Full Text] [Related]

  • 31. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
    Stanley WC, Marzilli M.
    Fundam Clin Pharmacol; 2003 Apr 23; 17(2):133-45. PubMed ID: 12667223
    [Abstract] [Full Text] [Related]

  • 32. [Medicines interacting with mitochondria: anti-ischemic effects of trimetazidine].
    Spedding M, Tillement JP, Morin D, Le Ridant A.
    Therapie; 1999 Apr 23; 54(5):627-35. PubMed ID: 10667101
    [Abstract] [Full Text] [Related]

  • 33. [Enhancement of antioxidant status of the elderly patients with ischemic heart disease in response to amino acid composition of MP-33 in combined therapy with trimetazidine].
    Kalinina EB, Komissarova IA, Zaslavskaia RM, Zhdanov IuA.
    Klin Med (Mosk); 2002 Apr 23; 80(5):50-3. PubMed ID: 12087889
    [Abstract] [Full Text] [Related]

  • 34. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC.
    Am J Cardiol; 2006 Sep 04; 98(5A):19J-24J. PubMed ID: 16931202
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C, Newby LK.
    Expert Rev Cardiovasc Ther; 2008 Jan 04; 6(1):9-16. PubMed ID: 18095903
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.